Office of the Vice Provost for ResearchEncouraging, cultivating, and coordinating high-impact academic research across Harvard’s schools and affiliated institutions
Faculty Disclosure for Federal Funding Agencies
OVPR has worked alongside the Sponsored Program offices (OSP and the ORA offices of HMS and HSPH) to update the NIH Biosketch and Other Support guidance and templates. Visit the Faculty Disclosure for Federal Funding Agencies webpage for more information on the implementation effective immediately and on or after January 25, 2022; as well as FAQs and the latest submission document templates and guides. All submissions, JIT requests, and RPPRs due on or after January 25, 2022, must adhere to the revised NIH requirements.
Featured Strategic Initiative: Landmark Bio, PBLLC
Spearheaded by the OVPR, Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today’s cutting-edge research into tomorrow’s breakthrough therapies. With construction starting on the new 40,000 square-foot biomanufacturing facility at The Arsenal on the Charles in Watertown, MA, Landmark Bio plans to begin opening at the start of 2022. The initial focus of the facility will include cell and gene therapy, gene editing, and mRNA products, which offer the potential to treat or even cure diseases such as cancer, diabetes, Parkinson’s, and Alzheimer’s, among others.